Abiomed, Inc.ABMDNASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank21
3Y CAGR-49.7%
5Y CAGR-39.8%
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

3Y CAGR
-49.7%/yr
vs -22.2%/yr prior
5Y CAGR
-39.8%/yr
Recent deceleration
Acceleration
-27.5pp
Decelerating
Percentile
P21
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
20223.94%
2021-12.81%
202024.87%
201930.98%
201867.26%
201749.90%
201677.40%
201584.48%
2014-11.11%
2013626.44%